Hans G. van Berkum
individual
About
Hans G. van Berkum is a pharmaceutical and biotech executive currently serving as CEO of Numeric Biotech, a company developing FOXO4-DRI senolytic therapies aimed at healthy aging and age-related disease. According to Numeric Biotech, he previously led Virosome Biologicals BV as CEO and board member until its acquisition by Norwood Immunology, and earlier held senior roles spanning regulatory affairs, medical leadership, and biotech commercialization at Astra, Roche, and Genzyme.
Areas of interest
longevitybiotechsenolyticspharmaceutical developmentregulatory affairsdrug commercializationhealthy aging